place. Creating such a test is largely complicated by intrinsic changes that occur during septic shock (e.g., alterations in free vs bound cortisol levels, glucocorticoid receptor binding activity, corticosteroid-binding proteins, and individualized responsiveness to corticosteroids) (1, 20). As the inherent difficulties in developing such a test continue to be investigated, practitioners who use steroids in patients with refractory septic shock may consider using them earlier on after diagnosis. The simple key continues to remain valid and that is late therapy fails to produce optimal outcomes in critically ill patients. 
9. Angus DC, van der Poll T: Severe sepsis and septic shock. U nderstanding the mechanisms that limit or propagate tissue injury during systemic inflammation may provide the basis for preventing secondary organ dysfunction during serious infections. Endotoxin, an outer membrane component of Gram-negative bacteria, is the archetypical microbial factor that mediates inflammation associated with these infections. Since the turn of the 20th century, the administration of endotoxin to humans has been used both as a therapy and as a tool to understand human inflammatory responses (1) (2) (3) (4) . Endotoxin has been administered to humans as a challenge agent by many different routes: IV infusions, lung exposure by inhalation or direct instillation, intradermal injection, application to the nasal mucosa, and oral ingestion. The resultant inflammatory responses depend on several factors including dose and route of administration and host factors, including gender, age, and diet. The availability of a reproducible model of human inflammation has afforded investigators www.ccmjournal.org
July 2014 • Volume 42 • Number 7 the opportunity to study different components of the response using both pathway specific and nonspecific therapies to alter these responses (i.e., cyclooxygenase inhibitors, corticosteroids, cytokine inhibitors, and anticoagulants) (1) .
When given IV, a series of dose-related phenomena occur. Very low doses (< 1 ng/kg body weight) result in minimal changes in vital signs, low levels of cytokines and a short period of depressed mood, reduced appetite, fatigue, and cognitive impairment (5) . In larger doses (2-4 ng/kg), endotoxin elicits a series of symptoms and signs that are qualitatively similar to the earliest phases of a true Gram-negative infection, including malaise, myalgias, headache, fever, increased heart and respiratory rates, a leukocytosis, a decrease in blood pressure, and the induction of a wide variety of inflammatory mediators in the blood. In contrast, when the lung is exposed by direct instillation of endotoxin into a segmental bronchus, a brisk local pulmonary inflammatory response ensues with minimal systemic effects, including low-level increases in blood interleukin (IL)-6, IL-1ra, granulocyte-colony stimulating factor, C-reactive protein (CRP), and a mild leukocytosis (6, 7). These models of inflammation are convenient but have several limitations. Endotoxin is only one of many microbial factors that are capable alone or with others to activate innate immune responses. Unlike bacteria, endotoxin is nonreplicating and a single low-dose exposure leads to a relatively short acute inflammatory response. It is within this narrow window of early inflammatory events that investigators attempt to define mechanisms associated with normal host immunity.
How do local or systemic inflammatory responses communicate with other tissue compartments (i.e., blood, lung, liver, and brain) to alter vital signs, produce acute phase proteins, activate cells, and lead to symptoms of illness? Conveying these responses across different tissue boundaries is presumed to occur in part through the integrated effects of transmigrating activated myeloid cells, circulating mediators, and neurohumoral factors. Previous studies in humans have shown that some communication exists between endotoxin-induced systemic inflammation and the lung compartment. Within the first 6 hours after IV endotoxin exposure, alveolar macrophages are primed to produce greater amounts of inflammatory mediators upon secondary stimulation (8). Furthermore, the lung exhibits increased clearance of small radiolabeled molecules suggesting an increase in lung permeability (9). Low levels of IL-8, IL-6, and G-CSF are present in bronchoalveolar lavage (BAL) at baseline, and these levels in the lung do not increase after IV endotoxin challenges (10) despite 10-to 100-fold peak increases in the blood.
In this issue of Critical Care Medicine, Plovsing et al (11) used both IV and lung endotoxin challenges to understand the interactions of systemic and local inflammatory responses. Healthy male subjects were randomized to undergo either an endotoxin challenge in the lung (by direct bronchial instillation) or a systemic challenge (IV administration). All the subjects underwent bronchoscopy with BAL at baseline and then at one of five time points (2, 4, 6, 8 , and 24 hr) after either their respective lung or IV endotoxin challenge. This approach allowed the authors to describe a time course of inflammatory events in each compartment (blood and lung) following either the IV or lung exposure. As noted by other investigators, IV endotoxin compared with lung challenge resulted in more intense signs and symptoms, elevated plasma levels of tumor necrosis factor, IL-6 and CRP, and higher levels of circulating total leukocytes and neutrophils (1, 4) . Lung challenge with endotoxin led to mild elevations of blood leukocytes, plasma IL-6, and CRP. The consequences of systemic inflammation on the lung were much less intense compared with the inflammatory response associated with direct lung challenge. At 8 or 24 hours after the IV challenge, BAL levels of total leukocytes and IL-6 were increased modestly without a concomitant increase in BAL total protein or albumin.
Was the secondary inflammatory response in the lung after IV endotoxin limited by the administered dose (4 ng per kg body weight)? A case report of the self-administration of an IV dose 3,750 times the dose given in the current study provides some insight into this question. The large dose of endotoxin resulted in vasopressor-dependent shock and acute kidney injury but only mild noncardiogenic pulmonary edema requiring 4 L of supplemental oxygen without the progression to severe acute lung injury (12). These data suggest that other factors (i.e., sustained inflammatory responses, other pathogen-associated mediators, and host genetic background) are required to cause disruption of lung alveolar-capillary integrity and lead to significant lung injury.
The authors of the current study conclude that a single dose of endotoxin elicited both primary and secondary inflammatory responses depending on the site of the initiating inflammatory stimulus. The novelty of their study was the simultaneous interrogation of both the lung and systemic compartments after either was exposed to endotoxin. However, the study was limited by its small size (i.e., each time point for BAL was performed on three subjects) and disproportionate changes in some of the measurements of left and right lung BAL biomarkers after IV endotoxin (i.e., one would expect comparable changes in biomarkers from different lung segments). This study demonstrates a temporal sequence of inflammatory events in the lung and may provide opportunities to use this approach to understand the signals and mechanisms that originate during systemic inflammation to affect lung function. C irrhosis is hard: the patients are hard to keep healthy, they are hard to take care of when ill, it is hard to mobilize both financial and institutional resources for their care, and the liver itself is literally hard. Patients with cirrhosis are complex, requiring multidisciplinary care and institutional coordination to adequately care for their needs. Patients with cirrhosis are prone to numerous complications, including refractory gastrointestinal hemorrhage, hepatic encephalopathy, hepatorenal syndrome, and infection (1). Furthermore, they can have hepatic decompensation, sometimes referred to as "acute-on-chronic liver failure," when these events occur. Patients with cirrhosis are often chronically hypotensive, which is often compounded by prophylactic β-blocker use, making shock that much more difficult to manage in this patient set. Septic shock is particularly problematic in this patient population, as patients with cirrhosis are prone to multidrug-resistant infections, renal failure, and adrenal insufficiency (1-3). In addition, infected patients really cannot receive a liver transplant unless adequately treated, although outcomes are reasonable once infections are adequately treated (4) . As the recovery rate for septic shock for patients with cirrhosis historically has been quite low (3, (5) (6) (7) , there is a sense of futility-in particular, for patients who are not a liver transplant candidate at all.
The Collège des Utilisateurs de Bases de données en Reanimation (CUB-Réa) Network was set up as an initiative of the Société de Réanimation de Lagnue Française in 1992 with initial funding from the Assistance Publique-Hôpitaux de Paris (8). The CUB-Réa Network has developed a prospectively maintained database derived from the ICUs of hospitals in Paris and its suburbs. Initially composed of 22 ICU, the group has grown. In this issue of Critical Care Medicine, Galbois et al (9) present their analysis of the CUB-Réa database for outcomes of patients with cirrhosis from septic shock. From over 31,000 patients with septic shock, they identified 2,383 patients with cirrhosis in 32 ICUs over a 13-year period. Similar to previous studies (6, 7), they found increased risk of death for the patients with cirrhosis (odds ratio [OR], 2.5; 95% CI, 2.3-2.8). Cirrhotic survivors were less likely to have required mechanical ventilation, renal replacement therapy, or transfusion. They also found that patients with cirrhosis in the second half of the study period had improved survival (OR, 0.7; 95% CI, 0.6-0.9), suggesting that care has improved over time, although the authors mute this conclusion somewhat, as the study is limited by the possibility that both formal and informal intensive care admission policies can change over time. In addition, survival data were censored for all living patients at time of discharge, the degree of cirrhosis could not be assessed from the available data, and the impact of liver transplantation following discharge from the ICU could not be factored into the analysis, as the data collection plan was based around the ICU admission. Despite these limitations, it is encouraging that the authors have shown an improvement in survival over time in a large multicenter study.
For the liver failure community, it is exciting to see improvements in survival. To others, it may seem that even with this improvement, outcomes are still not particularly promising. To help determine who may benefit from intensive care, there have been several attempts to apply scoring systems as predictive models. Childs-Turcotte-Pugh scoring has not been particularly useful prognostically in this setting (6) . Although the Model for End-Stage Liver Disease (MELD) scoring may have some predictive value for ICU patients (5), it is not particularly robust for prediction of in-hospital survival when compared with Sequential Organ Failure Assessment (SOFA) scoring (6), despite its predictive value for the severity of underlying cirrhosis. Not surprisingly, concurrent renal failure significantly increases
